(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Tributes pour in for James Ransone, 'The Wire' actor who died at 46 - 2Get To Be familiar with The Historical backdrop Of Western Medication
- 3UN mission says no evidence Hezbollah rearming in southern Lebanon
- 4Indian Health Service is digging out of decades-old construction backlog for medical buildings
- 5Yasser Abu Shabab's killing raises questions about Israel's militia strategy in Gaza
- Mechanical Sidekick d: A Survey of \Elements and Execution d\ Cell phone
- Russia patents space station designed to generate artificial gravity
- Virtual Route d: A Survey of \Exploring On the web Stages\ Web Administration
- Vote in favor of your Number one Kind of Shades
- I spent the last year transforming my life. Becoming a Rockette for a day made me confront a fear I couldn't shake.
- An Extended time of Careful Nurturing: Individual Bits of knowledge on Bringing up Kids
- Are protests pushing Iran's Islamic regime toward a tipping point?
- Old age isn’t a modern phenomenon – many people lived long enough to grow old in the olden days, too
- Major railway disruptions persist as Germany braces for more snow
